OK, that's what I wanted to hear,
"Botanix is actively investigating the reasons for for this unusual US response and is working with external experts in both clinical management and manufacturing to review the study conduct, operations and materials."
And the rest is good news too. Plenty of dosh on-hand. Re-hanging my portrait of Vince back over my bed again.
Ann: Appendix 4C - Quarterly, page-7
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.8¢ |
Change
0.008(2.08%) |
Mkt cap ! $665.1M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 37.0¢ | 35.3¢ | $822.6K | 2.277M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 232616 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 550950 | 10 |
View Market Depth
| Last trade - 13.56pm 26/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |